Impact of the 2022 pulmonary hypertension definition on haemodynamic classification and mortality in patients with aortic stenosis undergoing valve replacement
- PMID: 38812478
- PMCID: PMC11135639
- DOI: 10.1093/ehjopen/oeae037
Impact of the 2022 pulmonary hypertension definition on haemodynamic classification and mortality in patients with aortic stenosis undergoing valve replacement
Abstract
Aims: With the 2022 pulmonary hypertension (PH) definition, the mean pulmonary artery pressure (mPAP) threshold for any PH was lowered from ≥25 to >20 mmHg, and the pulmonary vascular resistance (PVR) value to differentiate between isolated post-capillary PH (IpcPH) and combined pre- and post-capillary PH (CpcPH) was reduced from >3 Wood units (WU) to >2 WU. We assessed the impact of this change in the PH definition in aortic stenosis (AS) patients undergoing aortic valve replacement (AVR).
Methods and results: Severe AS patients (n = 503) undergoing pre-AVR cardiac heart catheterization were classified according to both the 2015 and 2022 definitions. The post-AVR mortality [median follow-up 1348 (interquartile range 948-1885) days] was assessed. According to the 2015 definition, 219 (44% of the entire population) patients had PH: 63 (29%) CpcPH, 125 (57%) IpcPH, and 31 (14%) pre-capillary PH. According to the 2022 definition, 321 (+47%) patients were diagnosed with PH, and 156 patients (31%) were re-classified: 26 patients from no PH to IpcPH, 38 from no PH to pre-capillary PH, 38 from no PH to unclassified PH, 4 from pre-capillary PH to unclassified PH, and 50 from IpcPH to CpcPH (CpcPH: +79%). With both definitions, only the CpcPH patients displayed increased mortality (hazard ratios ≈ 4). Among the PH-defining haemodynamic components, PVR was the strongest predictor of death.
Conclusion: In severe AS, the application of the 2022 PH definition results in a substantially higher number of patients with any PH as well as CpcPH. With either definition, CpcPH patients have a significantly increased post-AVR mortality.
Keywords: Aortic stenosis; Definition; Pulmonary artery compliance; Pulmonary artery pressure; Pulmonary hypertension; Pulmonary vascular resistance.
© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology.
Conflict of interest statement
Conflict of interest: none declared.
Figures





Similar articles
-
Impact of the new pulmonary hypertension definition on long-term mortality in patients with severe aortic stenosis undergoing valve replacement.Clin Cardiol. 2021 Sep;44(9):1276-1285. doi: 10.1002/clc.23685. Epub 2021 Jul 4. Clin Cardiol. 2021. PMID: 34219245 Free PMC article.
-
Haemodynamic mechanisms and long-term prognostic impact of pulmonary hypertension in patients with severe aortic stenosis undergoing valve replacement.Eur J Heart Fail. 2019 Feb;21(2):172-181. doi: 10.1002/ejhf.1322. Epub 2018 Oct 17. Eur J Heart Fail. 2019. PMID: 30328215
-
Impact of Combined Pre and Postcapillary Pulmonary Hypertension on Survival after Transcatheter Aortic Valve Implantation.Am J Cardiol. 2020 Sep 15;131:60-66. doi: 10.1016/j.amjcard.2020.06.037. Epub 2020 Jun 30. Am J Cardiol. 2020. PMID: 32713655
-
The Diagnostic Challenge of Group 2 Pulmonary Hypertension.Prog Cardiovasc Dis. 2016 Jul-Aug;59(1):22-9. doi: 10.1016/j.pcad.2016.05.003. Epub 2016 May 16. Prog Cardiovasc Dis. 2016. PMID: 27195751 Review.
-
Updated Clinical Classification and Hemodynamic Definitions of Pulmonary Hypertension and Its Clinical Implications.J Cardiovasc Dev Dis. 2024 Feb 27;11(3):78. doi: 10.3390/jcdd11030078. J Cardiovasc Dev Dis. 2024. PMID: 38535101 Free PMC article. Review.
Cited by
-
The Monocrotaline Rat Model of Right Heart Disease Induced by Pulmonary Artery Hypertension.Biomedicines. 2024 Aug 23;12(9):1944. doi: 10.3390/biomedicines12091944. Biomedicines. 2024. PMID: 39335458 Free PMC article. Review.
References
-
- Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, Carlsen J, Coats AJS, Escribano-Subias P, Ferrari P, Ferreira DS, Ghofrani HA, Giannakoulas G, Kiely DG, Mayer E, Meszaros G, Nagavci B, Olsson KM, Pepke-Zaba J, Quint JK, Rådegran G, Simonneau G, Sitbon O, Tonia T, Toshner M, Vachiery JL, Vonk Noordegraaf A, Delcroix M, Rosenkranz S; ESC/ERS Scientific Document Group . 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2022;43:3618–3731. - PubMed
-
- Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, Ghofrani A, Gomez Sanchez MA, Hansmann G, Klepetko W, Lancellotti P, Matucci M, McDonagh T, Pierard LA, Trindade PT, Zompatori M, Hoeper M; ESC Scientific Document Group . 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 2016;37:67–119. - PubMed
-
- Maeder MT, Weber L, Weilenmann D, Chronis J, Joerg L, Pohle S, Haager PK, Brutsche M, Neumann T, Schoch OD, Rickli H. Impact of the new pulmonary hypertension definition on long-term mortality in patients with severe aortic stenosis undergoing valve replacement. Clin Cardiol 2021;44:1276–1285. - PMC - PubMed
LinkOut - more resources
Full Text Sources
Research Materials